Stock Events

Stock Events

Nykode Therapeutics AS 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 5VB.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap19.51B
Moderna is a leader in mRNA technology, directly competing in the vaccine and therapeutic space similar to Nykode's focus on novel immunotherapies.
BioNTech
BNTX
Mkt Cap22.92B
BioNTech competes in the development of novel mRNA vaccines and therapeutics, similar to Nykode's approach in immunotherapy.
Novavax
NVAX
Mkt Cap1.25B
Novavax is involved in the development of vaccines for infectious diseases, competing with Nykode's vaccine development efforts.
Pfizer
PFE
Mkt Cap161.09B
Pfizer develops and markets vaccines and therapeutics, including mRNA vaccines, competing in the same space as Nykode.
GSK
GSK
Mkt Cap113.29B
GlaxoSmithKline focuses on vaccines and therapeutics, including efforts in the immunotherapy space, making it a competitor.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson develops vaccines and therapeutics, including efforts in immunotherapy, competing with Nykode's product pipeline.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca is involved in the development of vaccines and therapeutics, including immunotherapy treatments, competing with Nykode.
Arcturus Therapeutics
ARCT
Mkt Cap228.24M
Arcturus Therapeutics is engaged in mRNA vaccine and therapeutic development, competing in the same technological space as Nykode.
Incyte
INCY
Mkt Cap19.09B
Incyte focuses on the discovery, development, and commercialization of therapeutics, including immunotherapies, making it a competitor in the same field as Nykode.

About

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
Show more...
CEO
Mr. Michael Thyring Engsig
Employees
59
Country
Germany
ISIN
NO0010714785

Listings

F
DE
5VB.F
MU
DE
5VB.MU
STU
DE
5VB.STU
OTC Link
US
VACBF

0 Comments

Share your thoughts

FAQ

What is Nykode Therapeutics AS stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Nykode Therapeutics AS stocks are traded under the ticker 5VB.MU.
How many employees does Nykode Therapeutics AS have?▼
As of April 11, 2026, the company has 59 employees.
In which sector is Nykode Therapeutics AS located?▼
Nykode Therapeutics AS operates in the Other sector.
When did Nykode Therapeutics AS complete a stock split?▼
Nykode Therapeutics AS has not had any recent stock splits.
Where is Nykode Therapeutics AS headquartered?▼
Nykode Therapeutics AS is headquartered in Oslo, Germany.